Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib

Lung cancer with complex epidermal growth factor receptor (EGFR) and CTNNB1 comutations is rare, and the efficacy of tyrosine kinase inhibitors (TKIs) is generally poor. Here, we encountered a lung cancer patient with complex EGFR (L858R and E709X) and CTNNB1 comutations who successfully responded t...

Descripción completa

Detalles Bibliográficos
Autores principales: Kunishige, Michihiro, Ichihara, Seiya, Kadota, Naoki, Okano, Yoshio, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Shinohara, Tsutomu, Takeuchi, Eiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891858/
https://www.ncbi.nlm.nih.gov/pubmed/36519636
http://dx.doi.org/10.1111/1759-7714.14775

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891858/
https://www.ncbi.nlm.nih.gov/pubmed/36519636
http://dx.doi.org/10.1111/1759-7714.14775

Ejemplares similares